Therapy News and Research

RSS

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome.

21 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children's Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy (SMA).

19 Oct 2013

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing five new Research Units. This was decided by the DFG Senate at its October meeting. The purpose of the research collaborations is to offer researchers the possibility to pursue current, pressing issues in their subject areas and to establish innovative work directions.

19 Oct 2013

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Patients who are responding below par to the anticoagulant drug warfarin have several options. They can undergo even more blood tests to monitor their response to the different dosages of this medication which is prescribed to prevent strokes, or they could start using one of the newer, yet more expensive, anticoagulants on the market.

19 Oct 2013

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Each week, KHN compiles a selection of recently released health policy studies and briefs.

19 Oct 2013

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

One of the challenges of understanding cancer is trying to determine the mechanisms that drive metastasis, or the process by which tumor cells are able to spread throughout the body.

19 Oct 2013

New prognostic tool forecasts survival of patients with advanced prostate cancer

For men with advanced prostate cancer that has progressed after taking hormones and undergoing chemotherapy, getting an accurate prognosis is critical to determine the next steps for treatment.

19 Oct 2013

Valley Presbyterian Hospital doc awarded 2013 Achievement Award in Diabetic Limb Salvage

George Andros, MD, Founder and Medical Director of the Amputation Prevention Center at Valley Presbyterian Hospital, was honored with the MedStar Georgetown 2013 Distinguished Achievement Award in Diabetic Limb Salvage.

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

CBT more effective in reducing symptoms of health anxiety

Cognitive behavioural therapy (CBT) is substantially more effective than standard care at reducing symptoms of health anxiety in medical patients, and can be delivered by non-specialist staff with minimal training at little extra cost.

19 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

18 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

18 Oct 2013

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

Genalyte, Inc., today announced that it has received a $1 million SBIR grant from the National Cancer Institute to develop a biomarker panel to profile tumor antigen-associated autoantibodies.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Therapy News and Research

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Study finds inherited GATA3 gene variation increases risk of developing pediatric leukemia

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

Five Research Units established to uncover physiological basis for cognitive processes, cultural techniques

New study guides clinicians and policy makers on cost-effectiveness of anticoagulant drugs

Research roundup: Less savings needed for retirement health expenses; falls as a predictor of surgical outcomes

Wnt5A signaling pathway helps researchers determine who may respond to BRAF inhibitors

New prognostic tool forecasts survival of patients with advanced prostate cancer

Valley Presbyterian Hospital doc awarded 2013 Achievement Award in Diabetic Limb Salvage

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

CBT more effective in reducing symptoms of health anxiety

Recombinant hormone could REPLACE calcium supplements

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News